Clinical-stage biotech developing RNAi medicines, led by anticoagulant CITY-FXI (Factor XI) plus eye-disease and anemia programs.
Clinical-stage biotech developing RNAi medicines, led by anticoagulant CITY-FXI (Factor XI) plus eye-disease and anemia programs.
Pre-revenue: funds early-stage trials from investor capital, including its October 2026 Nasdaq IPO. RNAi medicines switch off a gene's messenger RNA to cut production of a harmful protein, and the lead drug targets Factor XI, a clotting protein, as an anticoagulant. Co-founder John Maraganore, former Alnylam CEO, is executive chair; Bausch + Lomb and Biogen are research partners.
In one line: A smaller, earlier-stage Alnylam.
Moat: narrow (IP / patents, process know-how). Proprietary RNAi trigger designs and delivery conjugates; founders have RNAi drug-development experience.
Headquarters: Massachusetts, United States · Founded: 2023
Size City Therapeutics (CTY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $861M, the 2319th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.64 on 18 Nov 2026.
Growth Revenue grew 388.2% over the last twelve months (peer median +1.4%); the operating margin is -441.8% (peer median 1.4%).
Short interest Short interest is 1.6% of the free float (30 Oct 2026).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $13.6M | $2.78M |
| Revenue growth | — | +388% | — |
| Gross profit | n/a | $12.4M | $2.35M |
| EBITDA | n/a | -$58.8M | -$28.7M |
| Net income | n/a | -$58.5M | -$27.8M |
| Free cash flow | n/a | -$44.0M | -$23.9M |
| Capital expenditure | n/a | $2.40M | $3.54M |
| Total debt | n/a | $212M | $167M |
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| City Therapeutics CTY | $861M | n/a | +388% | -442% | n/a | n/a |
| Alnylam Pharmaceuticals ALNY | $20.0B | -50% | +56% | 20% | 3.9× | 0.5% |
| Arrowhead Pharmaceuticals ARWR | $6.09B | -44% | -46% | -157% | 14.0× | n/a |
| Ionis Pharmaceuticals IONS | $4.56B | -64% | -1% | -59% | 5.0× | n/a |
| Regeneron Pharmaceuticals REGN | $97.8B | +46% | +19% | 30% | 5.4× | -1.1% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CTY | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.1% | -10.5% | 4th lowest of 21 |
| Distance from 52-week high | -30.3% | -43.7% | 5th highest of 21 |
| Revenue growth (TTM) | +388.2% | +1.4% | highest of 19 |
| Operating margin | -441.8% | 1.4% | 4th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 0.9× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 1.2× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 1.2× | -4.2% | +10.6% |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 4.1× | 31.7% | +4.2% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | 0.8× | n/a | n/a |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | 15.3× | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 2.2× | 2.4% | +12.4% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 8.3× | 17.7% | +22.7% |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 5.8× | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | 4.7× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | 0.9× | -7.6% | -0.7% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | 33.4× | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | 13.8× | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | 6.5× | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | 7.0× | 27.7% | -39.5% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | 55.9× | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | 8.5× | n/a | n/a |